Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Avalo Therapeutics, Inc.

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.

Avalo Therapeutics | 2,687 followers on LinkedIn. Innovation driven by compassion. | Avalo Therapeutics is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize targeted therapeutics for patients with significant unmet clinical need. 

Our highly targeted therapeutics have strong scientific and clinical rationale that enable accelerated clinical development and increased probability of success.  

We are rapidly advancing a rich pipeline with broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.

Biotech Digital Landscape Leader | Digital and Transformation Leadership from Startup to Fortune 500 Company

Yingping Zhang

CEO, Independent Director, Physician-Scientist

Garry Neil

Chief Executive Officer at Clinical ink

Jonathan Goldman, MD MBA

Senior Director, Quality Assurance - Avalo Therapeutics

Tammy Updegrove

Avalo Therapeutics

Avalo is seeking a contractor to join our Clinical Operations team. If you have experience in clinical trials and a passion for advancing treatments through clinical development, check out the job post below! #clinicaltrials #development #immunology #clinops #contractor #biotech

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa https://lnkd.in/eJGtYVz4

We're #hiring a new Administrative Assistant in Wayne, Pennsylvania. Apply today or share this post with your network.

Avalo Therapeutics is pleased to welcome Mittie Doyle to our team as Chief Medical Officer. Mittie is a proven physician scientist and senior R&D leader with over 20 years of clinical development experience in the pharmaceutical/biotech industry and academia. Her expertise will be invaluable as we advance our portfolio, including initiating the Phase 2 program for AVTX-009, and continuing to pursue our mission to deliver novel therapeutics for patients with significant unmet clinical need. Welcome, Mittie! Read the full announcement here: https://bit.ly/4c27nzb

We're #hiring for a contract Clinical Operations Manager. Click below to apply today or share this post with your network! #clinical #clinicaltrials #contractor #clinops #clinicalstudy #development #biotech #therapeutics

Avalo Therapeutics is delighted to welcome Paul Varki to our team as Chief Legal Officer. Paul brings over 20 years of experience providing counsel in the pharmaceutical and biotech industry. His appointment underscores our commitment to strengthening our core leadership team and his deep industry experience and legal expertise will enhance our strategic and operational capabilities for future growth. Read the full announcement here: https://bit.ly/4eG99s3

We're #hiring a new Associate Director, Product Supply in Wayne, Pennsylvania. Click below to apply today or share this post with your network! #clinicalsupply #biotechnology #newjobalert #hiring #joinourteam #avalo

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million https://lnkd.in/ePTuMRun

Metric
Company Name	Avalo Therapeutics, Inc.
Symbol	AVTX
MSH ID	COM:AVALOTX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	19
Website	avalotx.com
LinkedIn	avalotx
Founders

Metric
Market Cap	12.97M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.41M
Revenue (LTM)
Revenue (NTM)
Gross Profit	124K
EBITDA	-27.87M
Operating Income	-27.87M
Net Income	-31.54M
EPS	-114
Diluted EPS	-114
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.60
Operating Profit Margin	-12.29
EBITDA Margin	-19.79
Net Profit Margin	-14.75
Return on Equity	14.04
Return on Assets	-0.33
Return on Capital Employed	0.22

COM:AVALOTX

Avalo Therapeutics, Inc.

Last Close

9.65

22/11 21:00

Market Cap

12.97M

Beta: -

Volume Today

80.44K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.75
P/B Ratio	12.98
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	134.38
EV Multiple	-0.48

Metric
Days Sales Outstanding	249.50
Days Payables Outstanding	135.46
Days Inventory Outstanding	0.17
Operating Cycle	249.67
Cash Conversion Cycle	114.21
Asset Turnover	0.09

Metric
Operating Cash Flow	-30.68M
Free Cash Flow	-30.68M
Cash Flow to Debt
Operating Cash Flow/Sales	-14.16
Free Cash Flow Yield	-9.76

Metric
Cash & Equivalents	7.42M
Accounts Receivable
Inventory
Goodwill	10.50M
Debt to Capitalization	0.26
Debt to Assets	0.02
Current Ratio	2.11
Quick Ratio	1.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.58
R&D to Revenue	8.04
SG&A to Revenue	4.69